Private Equity vs Strategics with Phil Vanek and Joe LaPlume

The third episode of season 2 of Phacilitate Talks allows us to finally visit a financial theme as we pitch private equity against strategics… 

Watch the full episode via the Phacilitate website: https://bit.ly/3nTtxy1  

Welcome to the third episode of season 2 of Phacilitate Talks! This week, we are finally able to re-visit our schedule as we discuss the financial landscape advanced therapies, pitching private equity against strategics.  

As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.   

Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG  

IN THE BLUE CORNER… 

In this episode, Anthony and Georgi are joined by Phil Vanek, CTO at Gamma Biosciences, and Joe LaPlume, Corporate Executive Vice President at Charles River Laboratories.  

The group discusses how the different companies operate, the importance of financial modelling, key headlines from a year of high investment, and how the two different companies or strategies might be able to work together before ‘going shopping’ for the perfect next opportunity for investment.  

QUICK LINKS 

• Phil Vanek: https://bit.ly/2W5g1fe  
• Joe LaPlume: https://bit.ly/3ksD8d0 
• Anthony Davies: https://bit.ly/3B7EQpJ    
• Christina Fuentes: https://bit.ly/2YSihaL   
• Georgi Makin: https://bit.ly/3jbg5Tj  

The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers. 

This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/